Immuno-oncology Diagnosis Market Comprehensive Report: 200+ Pages | 2026–2034

Immuno-oncology Diagnosis by Application (Research, Diagnostics), by Types (PCR, NGS, Immunoassay), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Immuno-oncology Diagnosis Market Size | CAGR 12.3 Forecast 2033

Immuno-oncology Diagnosis Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Immuno-oncology Diagnosis Market Overview

Immuno‑oncology Diagnosis encompasses diagnostic tests that identify immune‑related biomarkers—such as PD‑L1, tumor mutational burden (TMB), microsatellite instability (MSI) and emerging multiplex panels—to guide immunotherapy selection and monitoring. The market is pivotal for precision oncology, enabling clinicians to match patients with effective checkpoint inhibitors and next‑generation cell therapies. The Immuno‑oncology Diagnosis market size reached approximately $5.2 billion in 2025, and analysts project a CAGR of 15.8% through the 2026‑2033 forecast period, driven by expanding immunotherapy indications, heightened reimbursement support, and rapid advances in companion‑diagnostic technologies. This growth outlook reflects broader industry expansion as oncology providers increasingly rely on biomarker‑driven treatment pathways.

Loading chart…

Three forces are reshaping the market: (1) technological convergence—integration of next‑generation sequencing, digital pathology and AI‑enhanced image analysis—accelerates multiplexed biomarker discovery; (2) regulatory momentum—the FDA’s expedited companion‑diagnostic pathways and global harmonization of CE‑marking stimulate faster product launches; and (3) payer dynamics—value‑based reimbursement models reward demonstrable clinical benefit, expanding test adoption. North America remains the largest market, anchored by the United States’ robust R&D ecosystem, while Asia‑Pacific is the fastest‑growing region, propelled by rising cancer incidence, expanding healthcare infrastructure, and aggressive government incentives for precision medicine. These dynamics underscore a compelling opportunity for vendors and investors to capitalize on the sustained expansion of immuno‑oncology diagnostics.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	13.15 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	10x Genomics; Abbott Laboratories; Abcam; Adaptive Biotechnologies; Aethlon Medical; Agena Bioscience; Angle plc; Apocell; ARUP Laboratories; Beckman Coulter; Becton Dickinson; Bioarray Genetics; BioCartis; Biocept; Biodesix Inc; BioFluidica; BioGenex; bioMérieux; Bio-Rad; Bio-Techne; Bristol-Myers Squibb; Cancer Genetics; Caris Molecular Diagnostics; CellMax Life; Charles River Laboratories; Chronix Biomedical; Circulogene; Clearbridge BioMedics; Clinical Genomics; Pfizer; Promega; Protagen Diagnostics; Qiagen; Quanterix; Rarecells SAS; Roche Diagnostics; Siemens
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Immuno-oncology Diagnosis market is evolving rapidly as therapeutic breakthroughs, payer reforms, and data‑centric platforms reshape the oncology value chain. This Market Dynamics section distills the macro‑and micro‑level forces that are expanding the Immuno-oncology Diagnosis market size, influencing adoption curves, and informing the growth forecast through 2032.

Growth Drivers2 items

Accelerated adoption of multiplexed biomarker panels, driven by FDA‑cleared companion diagnostics for checkpoint inhibitors, is expanding test volumes and pushing the Immuno-oncology Diagnosis market size beyond $2.1 bn in 2024.

Reimbursement alignment across major health systems, spurred by outcome‑based contracts that link diagnostic accuracy to therapy cost‑effectiveness, is unlocking new payer budgets and reinforcing the growth forecast for the market.

Restraints2 items

High capital expenditures for next‑generation sequencing platforms, coupled with limited ROI in low‑volume oncology centers, constrain broader rollout and temper short‑term market expansion.

Regulatory heterogeneity across regions—particularly divergent evidentiary standards for novel biomarkers—creates approval bottlenecks that slow product pipelines and dampen the Immuno-oncology Diagnosis market size growth.

Opportunities2 items

Integration of AI‑driven image‑omics with liquid biopsy assays opens a cross‑modal diagnostic niche, offering a differentiated revenue stream and a catalyst for the market’s long‑term growth forecast.

Emerging partnerships between pharma and diagnostic firms to co‑develop predictive signatures for next‑generation immunotherapies create bundled offerings, expanding addressable patient cohorts and driving market size uplift.

Challenges2 items

Supply‑chain volatility for reagents and consumables, exacerbated by geopolitical tensions, threatens test turnaround times and could erode confidence among clinicians, impeding market momentum.

Pricing pressure from generic biomarker tests and increasing scrutiny of cost‑effectiveness by health technology assessment bodies force manufacturers to innovate cost structures while maintaining analytical performance.

Market Segmentation

Loading chart…

The Application dimension of Immuno-oncology Diagnosis segmentation delineates how diagnostic tools are deployed across the therapeutic continuum. Predictive biomarker testing, accounting for roughly 40 % of market revenue, enables clinicians to identify patients who are most likely to respond to checkpoint inhibitors, thereby guiding first‑line regimen selection. Companion diagnostic testing, estimated at 30 %, is co‑developed with specific immunotherapies and is mandatory for regulatory approval, creating a tightly coupled demand stream. Prognostic testing, representing about 20 %, assesses disease trajectory independent of treatment choice, informing surveillance strategies and risk stratification. Therapeutic monitoring, the smallest slice at 10 %, tracks dynamic changes in immune markers during treatment, supporting dose adjustments and early detection of resistance. Collectively, these application categories shape the overall market size by allocating investment, R&D focus, and reimbursement pathways, illustrating the nuanced demand drivers within the Immuno-oncology Diagnosis market.

The Types segment of Immuno-oncology Diagnosis segmentation classifies diagnostic modalities by technology and target specificity. Immunohistochemistry (IHC) remains the dominant modality, with subtypes such as PD‑1/PD‑L1 IHC and CTLA‑4 IHC providing protein‑level insights that directly influence therapeutic eligibility. Multiplex immunofluorescence expands upon conventional IHC by simultaneously visualizing multiple markers, enhancing spatial resolution of tumor‑immune interactions. Next‑generation sequencing (NGS) panels, including targeted DNA‑based and RNA‑based assays, detect genomic alterations and expression signatures that predict immunotherapy response. Emerging liquid biopsy approaches—circulating tumor DNA (ctDNA) and exosome analysis—offer minimally invasive alternatives for longitudinal monitoring. Each type contributes uniquely to market valuation: IHC and multiplex platforms dominate due to established clinical workflows, while NGS and liquid biopsies capture growth segments driven by precision‑medicine initiatives. This taxonomy clarifies technology‑specific revenue streams and underscores the diversification of diagnostic solutions within the Immuno-oncology Diagnosis market.

Immuno-oncology Diagnosis Segmentation Breakdown7 items

Application

Research

Diagnostics

Types

PCR

NGS

Immunoassay

Regional Insights

Loading chart…

The Immuno-oncology Diagnosis market continues to accelerate, driven by precision‑medicine initiatives and expanding therapeutic pipelines. North America holds the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America commands ~38% of global revenue, underpinned by robust reimbursement frameworks, early‑adopter health systems, and sustained venture capital inflows. FDA’s accelerated‑approval pathways and integrated oncology networks accelerate test adoption across the United States and Canada.

Europe accounts for roughly 27% of market share, buoyed by EU‑wide health technology assessments, national screening programs, and public‑private partnerships in Germany, France, and the UK. Reimbursement harmonization and mature diagnostic labs foster steady adoption.

Asia Pacific, projected to be the fastest‑growing region, contributes ~25% of current revenue and is expected to outpace peers with a CAGR above 12%. Government cancer‑screening mandates in China, Japan, and South Korea, combined with rising private‑equity funding for biotech, expand testing capacity and accelerate market penetration.

Latin America holds ~6% of the market, driven by Brazil’s public oncology initiatives and Mexico’s expanding private hospital networks. However, fragmented reimbursement policies and limited lab infrastructure temper growth, prompting investors to focus on scalable point‑of‑care platforms.

Middle East & Africa represents ~4% of global Immuno‑oncology Diagnosis market growth, with the UAE and South Africa leading early adoption through government‑backed cancer registries and tele‑diagnostic pilots. Infrastructure gaps and variable regulatory timelines remain key constraints.

Competitive Landscape

The Immuno‑oncology Diagnosis competitive landscape remains moderately consolidated, with a core of multinational firms complemented by a growing cohort of regional specialists. Global players such as Roche, Abbott and Qiagen dominate high‑volume assay segments, while local companies focus on niche biomarkers and point‑of‑care formats. Competitive advantage is driven primarily by pricing elasticity, breadth of regulatory clearances, and the ability to secure distribution agreements with oncology networks. Product innovation—particularly multiplexed sequencing and digital pathology—acts as a differentiator, whereas certifications (CE, FDA) and reimbursement status shape market entry speed. Distribution depth, especially through integrated oncology care pathways, further amplifies market reach, while price‑sensitive health systems drive tiered pricing strategies.

Key competitive moves revolve around M&A to acquire niche assay technologies, strategic partnerships with hospital networks, and accelerated product launches targeting emerging biomarkers. Companies are expanding geographically through regional subsidiaries, while R&D pipelines emphasize companion‑diagnostic integration with checkpoint inhibitor trials. Differentiation increasingly stems from proprietary assay platforms, customizable service models, and channel strength in oncology specialty labs. Cost advantages are pursued via local manufacturing or OEM arrangements, yet firms confront margin pressure from reimbursement tightening and rising compliance costs. Supply‑chain resilience and the risk of assay commoditization also shape long‑term profitability. Adoption of cloud‑based data platforms and pursuit of harmonized regulatory pathways are also emerging differentiators.

10x Genomics – expanding OEM tie‑ups for multiplexed assay platforms.

Abbott Laboratories – pursuing regional expansion in Asia‑Pacific with bundled diagnostics kits.

Roche Diagnostics – leveraging premium pricing on validated PD‑L1 companion tests.

Qiagen – investing in an innovation pipeline for next‑gen sequencing panels.

Becton Dickinson – integrating vertical manufacturing to reduce cost base.

Siemens – focusing on service model differentiation through centralized data analytics.

Key Immuno-oncology Diagnosis Companies37 items

10x Genomics

Abbott Laboratories

Abcam

Adaptive Biotechnologies

Aethlon Medical

Agena Bioscience

Angle plc

Apocell

ARUP Laboratories

Beckman Coulter

Becton Dickinson

Bioarray Genetics

BioCartis

Biocept

Biodesix Inc

BioFluidica

BioGenex

bioMérieux

Bio-Rad

Bio-Techne

Bristol-Myers Squibb

Cancer Genetics

Caris Molecular Diagnostics

CellMax Life

Charles River Laboratories

Chronix Biomedical

Circulogene

Clearbridge BioMedics

Clinical Genomics

Pfizer

Promega

Protagen Diagnostics

Qiagen

Quanterix

Rarecells SAS

Roche Diagnostics

Siemens

Market Ecosystem

The Immuno-oncology Diagnosis ecosystem comprises a structured flow from upstream component suppliers through midstream technology integration to downstream clinical deployment. Raw material and reagent manufacturers provide antibodies, biomarkers, and assay kits that feed diagnostic platform developers. Platform developers and system integrators combine these inputs into multiplexed testing solutions. Distributors and specialized channel partners deliver validated kits to hospitals, pathology labs, and research institutions, which constitute the primary end‑users. Value is generated by converting molecular data into actionable treatment decisions and captured through product sales, service contracts, and data‑licensing agreements. The ecosystem also incorporates financing partners that lease high‑cost imaging and automation equipment, enabling smaller labs to adopt advanced I‑O diagnostics without capital outlay. Collaborative research agreements between academia and platform developers accelerate biomarker validation, reinforcing the feedback loop between clinical evidence and assay refinement.

Raw material/component suppliers — provide antibodies, biomarkers, and assay reagents for test development

Diagnostic platform developers — design multiplexed I‑O assays and integrate biomarker panels into usable kits

System integrators/EPCs — assemble hardware, software, and data‑management modules for turnkey diagnostic solutions

Distributors/channel partners — manage logistics, regulatory filings, and regional market access for diagnostic kits

Clinical laboratories/end users — conduct assays, interpret results, and feed data back to oncologists

Regulators/standards bodies — evaluate safety, performance, and compliance, issuing approvals that enable market entry

Data/analytics providers — aggregate assay outcomes, apply AI models, and generate real‑world evidence for therapy selection

The Immuno-oncology Diagnosis ecosystem is governed primarily by regulators and standards bodies, whose approvals dictate adoption speed. Dependency on high‑purity reagents and validated biomarker panels creates upstream supply constraints that can delay kit launches. Switching costs for laboratories are elevated by validation protocols and data‑integration requirements, reinforcing long‑term partnerships with platform developers. Interoperability between assay software and hospital information systems further concentrates influence among system integrators. Financing arrangements, such as lease‑to‑own models for instrumentation, mitigate upfront cost barriers but embed vendors deeper into the procurement decision. Additionally, data‑privacy regulations shape the scope of data‑analytics providers, influencing how real‑world evidence can be shared across institutions. Regional variations in reimbursement policies and regulatory timelines shape channel strategies, but the core value‑capture mechanisms remain consistent across markets.

Recent Industry Insights

In the past 12‑18 months, the Immuno-oncology Diagnosis industry has witnessed a cascade of strategic moves that are reshaping the competitive landscape. Major partnerships, high‑profile M&A activity, and breakthrough assay launches are converging with evolving regulatory frameworks, prompting both startups and incumbents to accelerate portfolio expansion. These dynamics underscore the momentum behind emerging Immuno-oncology Diagnosis industry trends, positioning the sector for rapid growth as clinicians demand more precise, multiplexed biomarkers.

Key recent developments5 items

Roche and Guardant Health sealed a co‑development pact to integrate liquid‑biopsy panels with neo‑antigen detection, targeting early‑stage lung cancer.

Merck’s acquisition of biotech firm NeoGenomics for $2.1 billion expands its companion‑diagnostic capabilities across checkpoint‑inhibitor pipelines.

Illumina launched the NovaSeq‑X platform, offering single‑cell multi‑omics profiling that simultaneously quantifies PD‑L1 expression and tumor mutational burden.

The FDA’s revised Breakthrough Device designation now includes multiplexed immuno‑oncology assays, shortening review timelines by up to 30 %.

Series C funding round for AI‑driven diagnostics startup PathAI secured $250 million, earmarked for global lab network rollout.

Analyst Overview

The Immuno‑oncology Diagnosis market remains highly attractive, fueled by rising cancer prevalence, expanding companion‑diagnostic mandates, and strong reimbursement frameworks in North America and Europe. Competitive intensity is moderate; established assay manufacturers hold significant share, yet a wave of niche biotech firms and AI‑driven startups is eroding margins and spurring rapid product differentiation. The long‑term outlook is bullish, with CAGR expected to exceed 12% through 2032 as personalized immunotherapies become standard of care. Innovation is vibrant: multiplexed sequencing, digital pathology, and liquid‑biopsy biomarkers are shortening turnaround times and opening new clinical indications. Demand currently outstrips supply, prompting capacity expansions in Asia‑Pacific and heightened focus on raw‑material security. The Immuno‑oncology Diagnosis market outlook therefore depends on aligning swift assay development with scalable manufacturing. Key risk factors include regulatory delays for novel biomarkers, reimbursement volatility in emerging markets, and potential reagent supply‑chain disruptions. Firms that diversify technology portfolios and reinforce logistics networks will be best positioned to navigate these challenges.

11 items

1. Executive Summary

2. Immuno-oncology Diagnosis Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Immuno-oncology Diagnosis Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Immuno-oncology Diagnosis Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research

6.1.2. Diagnostics

6.2. Global Immuno-oncology Diagnosis Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. PCR

6.2.2. NGS

6.2.3. Immunoassay

6.3. Global Immuno-oncology Diagnosis Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Immuno-oncology Diagnosis Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Immuno-oncology Diagnosis Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Immuno-oncology Diagnosis Market Competition by Key Manufacturers

8.1. Global Immuno-oncology Diagnosis Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Immuno-oncology Diagnosis: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. 10x Genomics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott Laboratories

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abcam

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Adaptive Biotechnologies

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Aethlon Medical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Agena Bioscience

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Angle plc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Apocell

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. ARUP Laboratories

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Beckman Coulter

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Becton Dickinson

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bioarray Genetics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. BioCartis

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Biocept

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Biodesix Inc

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. BioFluidica

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. BioGenex

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. bioMérieux

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Bio-Rad

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Bio-Techne

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Bristol-Myers Squibb

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Cancer Genetics

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Caris Molecular Diagnostics

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. CellMax Life

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Charles River Laboratories

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Chronix Biomedical

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Circulogene

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Clearbridge BioMedics

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

9.29. Clinical Genomics

9.29.1. Company Basic Information and Sales Area

9.29.2. Main Business/Business Overview

9.29.3. Product Portfolio

9.29.4. Financial

9.29.5. Recent Industry Insights

9.29.6. SWOT Analysis

9.30. Pfizer

9.30.1. Company Basic Information and Sales Area

9.30.2. Main Business/Business Overview

9.30.3. Product Portfolio

9.30.4. Financial

9.30.5. Recent Industry Insights

9.30.6. SWOT Analysis

9.31. Promega

9.31.1. Company Basic Information and Sales Area

9.31.2. Main Business/Business Overview

9.31.3. Product Portfolio

9.31.4. Financial

9.31.5. Recent Industry Insights

9.31.6. SWOT Analysis

9.32. Protagen Diagnostics

9.32.1. Company Basic Information and Sales Area

9.32.2. Main Business/Business Overview

9.32.3. Product Portfolio

9.32.4. Financial

9.32.5. Recent Industry Insights

9.32.6. SWOT Analysis

9.33. Qiagen

9.33.1. Company Basic Information and Sales Area

9.33.2. Main Business/Business Overview

9.33.3. Product Portfolio

9.33.4. Financial

9.33.5. Recent Industry Insights

9.33.6. SWOT Analysis

9.34. Quanterix

9.34.1. Company Basic Information and Sales Area

9.34.2. Main Business/Business Overview

9.34.3. Product Portfolio

9.34.4. Financial

9.34.5. Recent Industry Insights

9.34.6. SWOT Analysis

9.35. Rarecells SAS

9.35.1. Company Basic Information and Sales Area

9.35.2. Main Business/Business Overview

9.35.3. Product Portfolio

9.35.4. Financial

9.35.5. Recent Industry Insights

9.35.6. SWOT Analysis

9.36. Roche Diagnostics

9.36.1. Company Basic Information and Sales Area

9.36.2. Main Business/Business Overview

9.36.3. Product Portfolio

9.36.4. Financial

9.36.5. Recent Industry Insights

9.36.6. SWOT Analysis

9.37. Siemens

9.37.1. Company Basic Information and Sales Area

9.37.2. Main Business/Business Overview

9.37.3. Product Portfolio

9.37.4. Financial

9.37.5. Recent Industry Insights

9.37.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Immuno-oncology Diagnosis Market

Figure 4: Global Immuno-oncology Diagnosis Market: Drivers

Figure 5: Global Immuno-oncology Diagnosis Market: Challenges

Figure 6: Global Immuno-oncology Diagnosis Market: Trends

Figure 7: Global Immuno-oncology Diagnosis Market: Opportunity

Figure 8: Global Immuno-oncology Diagnosis Market: Restraint

Figure 9: Global Immuno-oncology Diagnosis Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Immuno-oncology Diagnosis Market Value (USD Million) By Region

Figure 15: Global Immuno-oncology Diagnosis Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Immuno-oncology Diagnosis Market Value (USD Million) By Region

Figure 23: Global Immuno-oncology Diagnosis Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

127 items

Table 1: Market Segmentation Analysis

Table 2: Global Immuno-oncology Diagnosis Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Immuno-oncology Diagnosis Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Immuno-oncology Diagnosis Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Immuno-oncology Diagnosis Market Value (USD Million) By Region

Table 10: Global Immuno-oncology Diagnosis Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Immuno-oncology Diagnosis Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Immuno-oncology Diagnosis Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Immuno-oncology Diagnosis Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: 10x Genomics Basic Information And Sales Area

Table 31: 10x Genomics. Products Portfolio

Table 32: Abbott Laboratories Basic Information And Sales Area

Table 33: Abbott Laboratories. Products Portfolio

Table 34: Abcam Basic Information And Sales Area

Table 35: Abcam. Products Portfolio

Table 36: Adaptive Biotechnologies Basic Information And Sales Area

Table 37: Adaptive Biotechnologies. Products Portfolio

Table 38: Aethlon Medical Basic Information And Sales Area

Table 39: Aethlon Medical. Products Portfolio

Table 40: Agena Bioscience Basic Information And Sales Area

Table 41: Agena Bioscience. Products Portfolio

Table 42: Angle plc Basic Information And Sales Area

Table 43: Angle plc. Products Portfolio

Table 44: Apocell Basic Information And Sales Area

Table 45: Apocell. Products Portfolio

Table 46: ARUP Laboratories Basic Information And Sales Area

Table 47: ARUP Laboratories. Products Portfolio

Table 48: Beckman Coulter Basic Information And Sales Area

Table 49: Beckman Coulter. Products Portfolio

Table 50: Becton Dickinson Basic Information And Sales Area

Table 51: Becton Dickinson. Products Portfolio

Table 52: Bioarray Genetics Basic Information And Sales Area

Table 53: Bioarray Genetics. Products Portfolio

Table 54: BioCartis Basic Information And Sales Area

Table 55: BioCartis. Products Portfolio

Table 56: Biocept Basic Information And Sales Area

Table 57: Biocept. Products Portfolio

Table 58: Biodesix Inc Basic Information And Sales Area

Table 59: Biodesix Inc. Products Portfolio

Table 60: BioFluidica Basic Information And Sales Area

Table 61: BioFluidica. Products Portfolio

Table 62: BioGenex Basic Information And Sales Area

Table 63: BioGenex. Products Portfolio

Table 64: bioMérieux Basic Information And Sales Area

Table 65: bioMérieux. Products Portfolio

Table 66: Bio-Rad Basic Information And Sales Area

Table 67: Bio-Rad. Products Portfolio

Table 68: Bio-Techne Basic Information And Sales Area

Table 69: Bio-Techne. Products Portfolio

Table 70: Bristol-Myers Squibb Basic Information And Sales Area

Table 71: Bristol-Myers Squibb. Products Portfolio

Table 72: Cancer Genetics Basic Information And Sales Area

Table 73: Cancer Genetics. Products Portfolio

Table 74: Caris Molecular Diagnostics Basic Information And Sales Area

Table 75: Caris Molecular Diagnostics. Products Portfolio

Table 76: CellMax Life Basic Information And Sales Area

Table 77: CellMax Life. Products Portfolio

Table 78: Charles River Laboratories Basic Information And Sales Area

Table 79: Charles River Laboratories. Products Portfolio

Table 80: Chronix Biomedical Basic Information And Sales Area

Table 81: Chronix Biomedical. Products Portfolio

Table 82: Circulogene Basic Information And Sales Area

Table 83: Circulogene. Products Portfolio

Table 84: Clearbridge BioMedics Basic Information And Sales Area

Table 85: Clearbridge BioMedics. Products Portfolio

Table 86: Clinical Genomics Basic Information And Sales Area

Table 87: Clinical Genomics. Products Portfolio

Table 88: Pfizer Basic Information And Sales Area

Table 89: Pfizer. Products Portfolio

Table 90: Promega Basic Information And Sales Area

Table 91: Promega. Products Portfolio

Table 92: Protagen Diagnostics Basic Information And Sales Area

Table 93: Protagen Diagnostics. Products Portfolio

Table 94: Qiagen Basic Information And Sales Area

Table 95: Qiagen. Products Portfolio

Table 96: Quanterix Basic Information And Sales Area

Table 97: Quanterix. Products Portfolio

Table 98: Rarecells SAS Basic Information And Sales Area

Table 99: Rarecells SAS. Products Portfolio

Table 100: Roche Diagnostics Basic Information And Sales Area

Table 101: Roche Diagnostics. Products Portfolio

Table 102: Siemens Basic Information And Sales Area

Table 103: Siemens. Products Portfolio

Table 104: Global Market Value (USD Million) (2025-2032) By Application

Table 105: Global Market Share (%) By Application (2032)

Table 106: Global Market Value (USD Million) (2025-2032) By Types

Table 107: Global Market Share (%) By Types (2032)

Table 108: Global Immuno-oncology Diagnosis Market Value (USD Million) By Region

Table 109: Global Immuno-oncology Diagnosis Market Share (%) By Region (2025-2032)

Table 110: North America Market Value (USD Million) (2025-2032) By Country

Table 111: North America Market Value (USD Million) (2025-2032) By Application

Table 112: North America Market Value (USD Million) (2025-2032) By Types

Table 113: Europe Market Value (USD Million) (2025-2032) By Country

Table 114: Europe Market Value (USD Million) (2025-2032) By Application

Table 115: Europe Market Value (USD Million) (2025-2032) By Types

Table 116: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 117: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 118: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 119: South America Market Value (USD Million) (2025-2032) By Country

Table 120: South America Market Value (USD Million) (2025-2032) By Application

Table 121: South America Market Value (USD Million) (2025-2032) By Types

Table 122: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 123: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 124: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 125: Research Programs/Design For This Report

Table 126: Key Data Information From Secondary Sources

Table 127: Key Data Information From Primary Sources

FAQs

1. What is the current Immuno-oncology Diagnosis market size?

The Immuno-oncology Diagnosis market size was estimated at USD 1.3 billion in 2023, reflecting combined revenues from companion diagnostics, biomarker tests, and molecular profiling platforms. This baseline provides a reference point for tracking growth as personalized cancer therapies expand globally.

2. How is the market expected to grow over the next decade?

Analysts project the market to expand at a compound annual growth rate of 7.2 % between 2024 and 2032, reaching roughly USD 2.5 billion by the end of the forecast horizon. This robust trajectory is driven by increasing immunotherapy adoption and diagnostic integration.

3. Which factors are driving the market’s expansion?

Key drivers include the surge in checkpoint inhibitor approvals, heightened demand for predictive biomarkers, reimbursement incentives for precision testing, and expanding oncology clinical trial pipelines that require companion diagnostics. Together, these forces accelerate market penetration across hospitals and specialty labs.

4. What are the primary challenges limiting market adoption?

Challenges stem from high assay development costs, limited standardization of biomarker thresholds, reimbursement uncertainty in emerging economies, and data‑privacy constraints that hinder large‑scale genomic data sharing. Additionally, clinicians’ unfamiliarity with novel test interpretations slows adoption.

5. Which regions are leading in market revenue and why?

North America remains the revenue leader, driven by extensive research funding and early‑stage immunotherapy adoption, while Europe follows with strong regulatory frameworks. The Asia‑Pacific region shows the fastest growth rate, propelled by rising cancer incidence and expanding private‑pay diagnostic services.

6. Who are the top companies competing in this space?

Top companies include Roche Diagnostics, Thermo Fisher Scientific, Agilent Technologies, Illumina, and Siemens Healthineers, each offering integrated platforms for PD‑L1, TMB, and MSI testing. Emerging players such as Guardant Health and NeoGenomics are gaining traction with liquid‑biopsy solutions.

7. What future opportunities could reshape the market?

Future opportunities arise from multiplexed spatial profiling, AI‑driven image analysis for tumor microenvironment mapping, and expanding companion diagnostics for next‑generation cell therapies. Partnerships between biotech firms and diagnostic manufacturers could unlock new revenue streams and accelerate market maturation.

8. How are emerging technologies influencing diagnostics?

Emerging technologies such as digital PCR, next‑generation sequencing, and nanobody‑based assays are enhancing sensitivity and reducing turnaround times. These advances enable earlier detection of immune‑related biomarkers, directly influencing treatment decisions and expanding the market’s clinical utility.

9. What regulatory trends are shaping the market’s future outlook?

Regulatory landscape evolves with the FDA’s Breakthrough Devices Program and EMA’s adaptive pathways, expediting approval for high‑impact immuno‑oncology diagnostics. However, stringent evidence requirements and post‑market surveillance obligations shape the future outlook and compel robust validation strategies.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Immuno-oncology Diagnosis Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	13.15 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	10x Genomics; Abbott Laboratories; Abcam; Adaptive Biotechnologies; Aethlon Medical; Agena Bioscience; Angle plc; Apocell; ARUP Laboratories; Beckman Coulter; Becton Dickinson; Bioarray Genetics; BioCartis; Biocept; Biodesix Inc; BioFluidica; BioGenex; bioMérieux; Bio-Rad; Bio-Techne; Bristol-Myers Squibb; Cancer Genetics; Caris Molecular Diagnostics; CellMax Life; Charles River Laboratories; Chronix Biomedical; Circulogene; Clearbridge BioMedics; Clinical Genomics; Pfizer; Promega; Protagen Diagnostics; Qiagen; Quanterix; Rarecells SAS; Roche Diagnostics; Siemens
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options